|
시장보고서
상품코드
1983324
종양 정밀의료 시장 : 컴포넌트별, 케어 패스웨이 단계별, 기술별, 바이오마커 유형별, 검체 유형별, 최종사용자별, 암 유형별, 상환 및 액세스 채널별, 지역별Oncology Precision Medicine Market, By Component, By Care Pathway Stage, By Technology, By Biomarker Type, By Sample Type, End User, By Cancer Type, By Reimbursement & Access Channel, By Geography |
||||||
가격
※ 부가세 별도
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
종양 정밀의료 시장은 2026년에 1,905억 달러로 추정되고 있으며, 2033년까지 3,665억 3,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 9.8%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 1,905억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 9.80% | 2033년 시장 규모 예측 : | 3,665억 3,000만 달러 |
세계 종양 정밀의료 시장은 암 치료의 획기적인 패러다임 전환을 의미하며, 의료진이 진단, 치료법 선택, 환자 관리 방식을 근본적으로 변화시키고 있습니다. 종양 정밀의학은 첨단 유전체 염기서열 분석, 바이오마커 식별, 분자진단, 인공지능을 활용하여 환자 개개인의 프로파일과 특정 종양 특성에 맞는 고도로 맞춤화된 치료 중재를 제공합니다.
이 혁신적인 접근법은 기존의 획일적인 조사 방법을 넘어 임상의가 각 환자의 악성 종양에 특화된 유전자 변이, 단백질 발현, 세포 경로를 기반으로 최적의 치료 경로를 식별할 수 있게 해줍니다. 차세대 염기서열분석(NGS), 액체생검, 약물유전체학, 동반진단 등 첨단 기술의 통합으로 우수한 효능과 부작용 감소를 보이는 표적치료제, 면역치료제 및 병용치료 프로토콜의 개발이 가속화되고 있습니다. 전 세계 의료시스템이 가치 기반 치료 모델을 채택하고 비용 관리와 환자 예후 개선을 위해 노력하는 가운데, 정밀의학은 폐암, 유방암, 대장암, 흑색종, 혈액암 등 다양한 암종에서 치료 효과를 높이고 시행착오를 최소화하며 궁극적으로 생존율을 향상시키는 중요한 솔루션으로 부상하고 있습니다. 생존율을 향상시킬 수 있는 매우 중요한 해결책으로 떠오르고 있습니다.
시장 역학
세계 종양 정밀의료 시장은 몇 가지 강력한 시장 성장 촉진요인에 의해 주도되고 있으며, 전 세계 의료기관에서 시장 확대와 도입 속도를 계속 가속화하고 있습니다. 주요 성장 요인은 유전체 시퀀싱 기술의 비용이 빠르게 하락하고 있다는 점입니다. 이로 인해 정밀진단이 일상적인 임상에서 보다 쉽게 이용 가능하고 경제적으로도 실현 가능해졌지만, 전 세계에서 암 발병률이 증가함에 따라 보다 효과적이고 개인화된 치료 솔루션에 대한 수요가 급증하고 있습니다.
인공지능, 머신러닝 알고리즘, 빅데이터 분석의 기술 발전으로 의료진은 방대한 양의 유전체 데이터와 임상 데이터를 처리할 수 있게 되었고, 이를 통해 보다 정확한 치료 예측과 약물 선택 과정이 가능해졌습니다. 정부의 구상과 규제적 지원, 그리고 민관 모두 정밀의료 연구에 대한 막대한 투자로 시장 성장이 더욱 가속화되고 있으며, 미국 식품의약국(FDA)과 같은 기관은 동반진단 및 표적치료제 승인 절차를 간소화하고 있습니다.
그러나 이 시장은 특히 개발도상국의 높은 의료시설 도입 비용, 국가마다 다른 복잡한 규제 체계, 정밀의료 기술을 효과적으로 활용하기 위한 전문 인프라와 숙련된 인력의 필요성 등 심각한 제약에 직면해 있습니다. 데이터 프라이버시에 대한 우려, 유전자 검사를 둘러싼 윤리적 고려 사항, 특정 의료 시스템의 제한된 상환 정책도 시장 침투를 가로막고 있습니다.
그럼에도 불구하고 희귀암에 대한 적용 확대, 액체생검 기술의 확산, 바이오마커 기반 신약 개발을 위한 제약사와의 제휴 증가, 특히 의료의 디지털화가 가속화되고 개인 맞춤형 치료가 전 세계 종양학 진료의 표준 치료로 자리 잡으면서 정밀의료가 일상적인 임상 워크플로우에 통합될 수 있는 가능성은 큰 기회로 작용하고 있습니다. 워크플로우에 통합할 수 있는 가능성은 큰 기회를 창출하고 있습니다.
이 보고서의 주요 특징
- 세계의 암 정밀의학(Cancer Precision Medicine) 시장을 상세하게 분석하고, 2025년을 기준 연도로 하여 예측기간(2026-2033년) 시장 규모와 CAGR을 조사 분석하여 전해드립니다.
- 또한 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트을 제공합니다.
- 세계 암 정밀의학 시장의 주요 기업 개요을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 정리하여 수록했습니다.
- 이 보고서의 인사이트을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 암 정밀의학 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 암 정밀의학 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 종양 정밀의료 시장 : 컴포넌트별(2021-2033년)
제5장 세계의 종양 정밀의료 시장 : 케어 패스웨이 단계별(2021-2033년)
제6장 세계의 종양 정밀의료 시장 : 기술별(2021-2033년)
제7장 세계의 종양 정밀의료 시장 : 바이오마커 유형별(2021-2033년)
제8장 세계의 종양 정밀의료 시장 : 검체 유형별(2021-2033년)
제9장 세계의 종양 정밀의료 시장 : 최종사용자별(2021-2033년)
제10장 세계의 종양 정밀의료 시장 : 암 유형별(2021-2033년)
제11장 세계의 종양 정밀의료 시장 : 상환·액세스 채널별(2021-2033년)
제12장 세계의 종양 정밀의료 시장 : 지역별(2021-2033년), 시장 규모
제13장 경쟁 구도
제14장 애널리스트의 제안
제15장 참고 문헌 및 분석 방법
KSA 26.04.23Oncology Precision Medicine Market is estimated to be valued at USD 190.50 Bn in 2026 and is expected to reach USD 366.53 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 190.50 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 366.53 Bn |
The global oncology precision medicine market represents a revolutionary paradigm shift in cancer treatment, fundamentally transforming how healthcare providers approach diagnosis, treatment selection, and patient care management. Precision medicine in oncology leverages advanced genomic sequencing, biomarker identification, molecular diagnostics, and artificial intelligence to deliver highly personalized therapeutic interventions tailored to individual patient profiles and specific tumor characteristics.
This innovative approach moves beyond the traditional one-size-fits-all treatment methodology, enabling clinicians to identify optimal therapeutic pathways based on genetic mutations, protein expressions, and cellular pathways unique to each patient's malignancy. The integration of cutting-edge technologies such as next-generation sequencing (NGS), liquid biopsies, pharmacogenomics, and companion diagnostics has accelerated the development of targeted therapies, immunotherapies, and combination treatment protocols that demonstrate superior efficacy rates and reduced adverse effects. As healthcare systems worldwide increasingly adopt value-based care models and seek to improve patient outcomes while managing costs, precision medicine emerges as a critical solution that promises to enhance treatment response rates, minimize trial-and-error prescribing, and ultimately improve survival rates across various cancer types including lung, breast, colorectal, melanoma, and hematological malignancies.
Market Dynamics
The global oncology precision medicine market is propelled by several compelling drivers that continue to accelerate market expansion and adoption rates across healthcare institutions worldwide. The primary growth driver stems from the rapidly declining costs of genomic sequencing technologies, making precision diagnostics more accessible and economically viable for routine clinical implementation, while simultaneously increasing cancer incidence rates globally create an urgent demand for more effective, personalized treatment solutions.
Technological advancements in artificial intelligence, machine learning algorithms, and big data analytics enable healthcare providers to process vast amounts of genomic and clinical data, facilitating more accurate treatment predictions and drug selection processes. Government initiatives, regulatory support, and substantial investments in precision medicine research from both public and private sectors further accelerate market growth, with organizations like the U.S. FDA streamlining approval processes for companion diagnostics and targeted therapies.
However, the market faces significant restraints including high implementation costs for healthcare facilities, particularly in developing regions, complex regulatory frameworks that vary across different countries, and the need for specialized infrastructure and trained personnel to effectively utilize precision medicine technologies. Data privacy concerns, ethical considerations surrounding genetic testing, and limited reimbursement policies in certain healthcare systems also impede market penetration.
Nevertheless, substantial opportunities emerge from expanding applications in rare cancers, growing adoption of liquid biopsy technologies, increasing pharmaceutical partnerships for biomarker-driven drug development, and the potential for precision medicine integration into routine clinical workflows, particularly as healthcare digitization accelerates and personalized treatment becomes the standard of care across oncology practices globally.
Key Features of the Study
- This report provides in-depth analysis of the global oncology precision medicine market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global oncology precision medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include F. Hoffmann La Roche Ltd, Novartis AG, Pfizer Inc, AstraZeneca plc, Bristol Myers Squibb Company, Merck & Co Inc, Gilead Sciences Inc, Illumina Inc, Thermo Fisher Scientific Inc, QIAGEN NV, BioNTech SE, Amgen Inc, Foundation Medicine Inc, Guardant Health, and Myriad Genetics Inc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global oncology precision medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oncology precision medicine market
Market Segmentation
- Component Insights (Revenue, USD Bn, 2021 - 2033)
- Therapeutics
- Targeted therapies
- Targeted biologics
- Precision immuno-oncology
- Cell & gene therapies
- Radiotheranostics / targeted radionuclide therapies
- Combination regimens
- Diagnostics / Testing
- Companion diagnostics (CDx)
- Complementary diagnostics
- Comprehensive genomic profiling (CGP) panels
- Minimal residual disease (MRD) testing
- Pharmacogenomics (PGx) relevant to oncology regimens
- Informatics & Decision Support
- Clinical decision support (CDS) / treatment matching engines
- Variant interpretation & annotation platforms
- Molecular tumor board (MTB) enablement software
- Data integration (EHR/LIS/omics) & interoperability tools
- Services
- Sample logistics, biobanking, and pre-analytics services
- Bioinformatics services (pipeline, interpretation, reporting)
- Clinical trial matching services
- Real-world evidence (RWE) and outcomes analytics
- Contract research / companion diagnostic development services
- Care Pathway Stage (Revenue, USD Bn, 2021 - 2033)
- Risk assessment & screening
- Diagnosis & tumor classification
- Therapy selection
- Treatment monitoring
- Response monitoring
- Resistance emergence detection
- Dose/therapy optimization
- Recurrence surveillance / MRD
- Clinical trial enrolment & matching
- Technology (Revenue, USD Bn, 2021 - 2033)
- Genomics
- Next-generation sequencing (NGS)
- Targeted panels
- Whole exome sequencing (WES)
- Whole genome sequencing (WGS)
- PCR / qPCR / ddPCR
- Sanger sequencing (confirmatory)
- Transcriptomics
- RNA sequencing (RNA-seq)
- Gene expression profiling / signatures
- Proteomics / Protein biomarkers
- Immunohistochemistry (IHC)
- Mass spectrometry-based proteomics (select settings)
- Cytogenetics & Structural Variation
- FISH
- Karyotyping (certain hematologic cancers)
- Epigenetics
- DNA methylation profiling (select tumors)
- Liquid biopsy technologies
- ctDNA / cfDNA
- CTCs
- Exosomes / extracellular vesicles (emerging)
- Single-cell & spatial
- Single-cell sequencing (scRNA/scDNA)
- Spatial transcriptomics / multiplex imaging
- Biomarker Type (Revenue, USD Bn, 2021 - 2033)
- Genetic biomarkers
- Single nucleotide variants (SNVs)
- Indels
- Copy number variations (CNVs)
- Gene fusions / rearrangements
- Germline variants (hereditary cancer)
- Genomic signatures / global markers
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI)
- Homologous recombination deficiency (HRD)
- Expression / protein markers
- Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)
- Epigenetic biomarkers
- Methylation signatures
- MRD biomarkers
- Personalized tumor-informed MRD
- Tumor-naive MRD panels
- Sample Type (Revenue, USD Bn, 2021 - 2033)
- Tissue-based
- FFPE tissue
- Fresh frozen tissue
- Core needle biopsy / surgical specimens
- Blood-based (liquid biopsy)
- Plasma (ctDNA/cfDNA)
- Whole blood (CTCs, RNA)
- Other biofluids
- Urine, saliva, CSF (indication-dependent)
- Cytology samples
- FNA, smears (select workflows)
- End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals & cancer centers
- Diagnostic laboratories
- Clinical pathology labs
- Molecular/genetic labs
- Academic & research institutes
- Pharmaceutical & biotech companies
- CROs / clinical trial networks
- Payers / HTA bodies
- Cancer Type (Revenue, USD Bn, 2021 - 2033)
- Solid tumors
- Lung, breast, colorectal, prostate, ovarian, melanoma, pancreatic, gastric, head & neck, liver, kidney, brain/CNS, etc.
- Hematologic malignancies
- Leukemia, lymphoma, myeloma, MDS/MPN, etc.
- Rare cancers / tumor-agnostic segments
- Tumor-agnostic biomarker-defined populations
- Reimbursement & Access Channel (Revenue, USD Bn, 2021 - 2033)
- Public reimbursement
- Private reimbursement
- Out-of-pocket / self-pay
- Hybrid coverage models
- Patient assistance / access programs
- Clinical trial-funded testing
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Hoffmann La Roche Ltd
- Novartis AG
- Pfizer Inc
- AstraZeneca plc
- Bristol Myers Squibb Company
- Merck & Co Inc
- Gilead Sciences Inc
- Illumina Inc
- Thermo Fisher Scientific Inc
- QIAGEN NV
- BioNTech SE
- Amgen Inc
- Foundation Medicine Inc
- Guardant Health
- Myriad Genetics Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Oncology Precision Medicine Market, By Component
- Global Oncology Precision Medicine Market, By Care Pathway Stage
- Global Oncology Precision Medicine Market, By Technology
- Global Oncology Precision Medicine Market, By Biomarker Type
- Global Oncology Precision Medicine Market, By Sample Type
- Global Oncology Precision Medicine Market, By End User
- Global Oncology Precision Medicine Market, By Cancer Type
- Global Oncology Precision Medicine Market, By Reimbursement & Access Channel
- Global Oncology Precision Medicine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Oncology Precision Medicine Market, By Component, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Targeted therapies
- Targeted biologics
- Precision immuno-oncology
- Cell & gene therapies
- Radiotheranostics / targeted radionuclide therapies
- Combination regimens
- Diagnostics / Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Companion diagnostics (CDx)
- Complementary diagnostics
- Comprehensive genomic profiling (CGP) panels
- Minimal residual disease (MRD) testing
- Pharmacogenomics (PGx) relevant to oncology regimens
- Informatics & Decision Support
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical decision support (CDS) / treatment matching engines
- Variant interpretation & annotation platforms
- Molecular tumor board (MTB) enablement software
- Data integration (EHR/LIS/omics) & interoperability tools
- Services
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Sample logistics, biobanking, and pre-analytics services
- Bioinformatics services (pipeline, interpretation, reporting)
- Clinical trial matching services
- Real-world evidence (RWE) and outcomes analytics
- Contract research / companion diagnostic development services
5. Global Oncology Precision Medicine Market, By Care Pathway Stage, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Risk Assessment & Screening
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diagnosis & Tumor Classification
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Therapy Selection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Treatment Monitoring
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Response Monitoring
- Resistance Emergence Detection
- Dose/Therapy Optimization
- Recurrence Surveillance / MRD
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical Trial Enrolment & Matching
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Oncology Precision Medicine Market, By Technology, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Genomics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Next-generation sequencing (NGS)
- Targeted panels
- Whole exome sequencing (WES)
- Whole genome sequencing (WGS)
- PCR / qPCR / ddPCR
- Sanger sequencing (confirmatory)
- Transcriptomics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- RNA sequencing (RNA-seq)
- Gene expression profiling / signatures
- Proteomics / Protein biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunohistochemistry (IHC)
- Mass spectrometry-based proteomics (select settings)
- Cytogenetics & Structural Variation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- FISH
- Karyotyping (certain hematologic cancers)
- Epigenetics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- DNA methylation profiling (select tumors)
- Liquid biopsy technologies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- ctDNA / cfDNA
- CTCs
- Exosomes / extracellular vesicles (emerging)
- Single-cell & spatial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Single-cell sequencing (scRNA/scDNA)
- Spatial transcriptomics / multiplex imaging
7. Global Oncology Precision Medicine Market, By Biomarker Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Genetic Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Single nucleotide variants (SNVs)
- Indels
- Copy number variations (CNVs)
- Gene fusions / rearrangements
- Germline variants (hereditary cancer)
- Genomic Signatures / Global Markers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Tumor mutational burden (TMB)
- Microsatellite instability (MSI)
- Homologous recombination deficiency (HRD)
- Expression / Protein Markers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Receptor status, ligand expression, immune markers (e.g., checkpoint pathway expression classes)
- Epigenetic Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Methylation signatures
- MRD Biomarkers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Personalized tumor-informed MRD
- Tumor-naive MRD panels
8. Global Oncology Precision Medicine Market, By Sample Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Tissue-based
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- FFPE tissue
- Fresh frozen tissue
- Core needle biopsy / surgical specimens
- Blood-based (liquid biopsy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Plasma (ctDNA/cfDNA)
- Whole blood (CTCs, RNA)
- Other Biofluids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Urine, saliva, CSF (indication-dependent)
- Cytology Samples
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- FNA, Smears (Select Workflows)
9. Global Oncology Precision Medicine Market, By End User, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals & cancer centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Diagnostic laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical pathology labs
- Molecular/genetic labs
- Academic & research institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Pharmaceutical & biotech companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- CROs / clinical trial networks
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Payers / HTA bodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
10. Global Oncology Precision Medicine Market, By Cancer Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Solid Tumors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Lung, breast, colorectal, prostate, ovarian, melanoma, pancreatic, gastric, head & neck, liver, kidney, brain/CNS, etc.
- Hematologic Malignancies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Leukemia, lymphoma, myeloma, MDS/MPN, etc.
- Rare Cancers / Tumor-agnostic Segments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Tumor-agnostic biomarker-defined populations
11. Global Oncology Precision Medicine Market, By Reimbursement & Access Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Public Reimbursement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Private Reimbursement
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Out-of-pocket / Self-pay
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Hybrid coverage models
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Patient Assistance / Access Programs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Clinical trial-funded Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
12. Global Oncology Precision Medicine Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Component, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Care Pathway Stage, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Biomarker Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sample Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Cancer Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Reimbursement & Access Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Hoffmann La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Illumina Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Thermo Fisher Scientific Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- QIAGEN NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BioNTech SE
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Foundation Medicine Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Guardant Health
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Myriad Genetics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
샘플 요청 목록